October industry news: first patient dosed in long-term trial of bryostatin for Alzheimer’s disease

Written by Sharon Salt, Senior Editor

This month in industry, we hear more about how studies have enroled and dosed their first patients for pridopidine in early Huntington’s disease and bryostatin in Alzheimer’s disease, respectively. In addition to this, siponimod has become the first oral treatment recommended by both NICE and SMC for adults with secondary progressive multiple sclerosis; the DTM™ Spinal Cord Stimulation using Medtronic Intellis™ provides sustained back relief in patients; the NIMBUS™ geometric clot extractor has been launched in Europe for patients with acute ischemic stroke; and a 5-year collaboration has been announced to discover and develop novel treatments for amyotrophic lateral sclerosis...

To view this content, please register now for access

It's completely free